Get the Stockscreener App
903.02
1.83%
-16.88
After Hours:
914.00
10.98
+1.22%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $903.02, with a volume of 4.05M.
It is down -1.83% in the last 24 hours and down -0.41% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$919.90
Open:
$910.2
24h Volume:
4.05M
Relative Volume:
1.29
Market Cap:
$806.72B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
39.98
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-2.11%
1M Performance:
-0.41%
6M Performance:
+12.94%
1Y Performance:
+10.39%
1-Day Range:
$881.11
$913.05
1-Week Range:
$881.11
$930.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
903.02 | 821.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.16 | 555.64B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.12 | 360.31B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.78 | 311.24B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.97 | 288.11B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs - Courthouse News
Rigel Pharmaceuticals to regain rights to ocadusertib after Eli Lilly ends agreement - Investing.com
Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts - Proactive financial news
Eli Lilly (LLY) Receives Buy Rating Amid Growth Prospects for Ob - GuruFocus
Morgan Stanley reiterates Eli Lilly stock rating on Medicare coverage outlook - Investing.com India
UBS Pounds the Table on Eli Lilly Stock (LLY) After Kelonia Therapeutics Deal - TipRanks
Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. -- Barrons.com - 富途牛牛
Eli Lilly Stock (LLY) Opinions on Amazon's GLP-1 Program Launch - Quiver Quantitative
Eli Lilly and Co Stock (LLY) Moved Down by 3.52% on Apr 21: Key Drivers Unveiled - TradingKey
Eli Lilly stock price forecast: $850–$900 range as LLY declines 3.78% - Traders Union
Eli Lilly (LLY) Faces Challenges with Medicare Coverage for Weig - GuruFocus
Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion - GuruFocus
UBS reiterates Eli Lilly stock Buy rating after Kelonia deal By Investing.com - Investing.com India
UnitedHealth, Eli Lilly among market cap stock movers on Tuesday - Investing.com
Why Did Eli Lilly Stock Drop Today? - The Motley Fool
Guggenheim Adjusts Price Target on Eli Lilly to $1,183 From $1,163, Maintains Buy Rating - marketscreener.com
Eli Lilly backs crackdown on fake Mounjaro in Gurugram, flags safety risks - Business Standard
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,350 - 富途牛牛
AI Models Split on How Hard to Lean Into Eli Lilly’s Growth Story - TipRanks
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout - Pharmaceutical Technology
Eli Lilly strikes up to $7 billion deal to buy Kelonia Thera - The Pharma Letter
Eli Lilly proceeds with Goochland plant, but it hasn't bought the land - Richmond Times-Dispatch
Eli Lilly acquires CrossBridge Bio’s dual-payload ADC platform - Drug Target Review
Taiwan Semiconductor Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly Invests Weight-Loss Windfall in Next-Gen Cancer Treatment - The Daily Upside
Eli Lilly and Company stock (US5324571083): Why Google Discover changes matter more now for pharma i - AD HOC NEWS
GenScript Biotech rose more than 5% in early trading as Eli Lilly and Co announced a $7 billion acquisition of an in vivo CAR-T company. - 富途牛牛
Eli Lilly’s US$7b Kelonia Deal Expands Oncology And Valuation Opportunity - simplywall.st
Eli Lilly Expands Genetic Edge in Russell 1000 Index Race - Kalkine Media
Eli Lilly hedges against GLP-1 revenue drop-off with $7B acquisition - PitchBook
Eli Lilly Negotiates $2B+ Kelonia Therapeutics Acquisition to Boost Oncology PortfolioNews and Statistics - IndexBox
Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride - statnews.com
Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase In Years - Crunchbase News
Nuclear energy letter of intent with Eli Lilly and Co. - nwitimes.com
Why Eli Lilly Just Bought This Cancer Focused Biotech - Barron's
Eli Lilly: We Haven't Reached Its Peak Yet (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Eli Lilly Acquires Kelonia Therapeutics | PharmExec - Pharmaceutical Executive
[SCHEDULE 13G/A] ELI LILLY & Co Amended Passive Investment Disclosure - Stock Titan
What's Going On With Eli Lilly Stock Monday - TradingView
Eli Lilly to acquire Boston biotech Kelonia Therapy in $7 billion deal - Boston.com
Eli Lilly Acquires Kelonia Therapeutics for Up to $7B, Making Bold Entry Into In Vivo CAR-T Cell Therapy - Oncodaily
Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit - CNBC
Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline - Genetic Engineering and Biotechnology News
Indiana partners with Eli Lilly to explore nuclear power possibilities - nwitimes.com
Kirkland, Goodwin Guide Lilly's Potential $7B Kelonia Buy - Law360
Lilly to buy Boston biotech Kelonia for $3.25 billion in latest Mass. investment - The Boston Globe
Eli Lilly and Co will acquire Kelonia for up to $7 billion, bolstering its cancer treatment pipeline. - 富途牛牛
Eli Lilly: Up To $7 Billion Acquisition Of Kelonia Advances In Vivo CAR-T Therapies - Pulse 2.0
Braun announces Indiana and Lilly pharmaceutical will partner to explore nuclear energy - Indiana Public Media
Lilly's plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer's fate? - drugdiscoverytrends.com
RBC reiterates Eli Lilly stock Outperform on Kelonia acquisition By Investing.com - Investing.com South Africa
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):